

Resveratrol, a popular dietary supplement for human and animal health: Quantitative research literature analysis - a review

Andy Wai Kan Yeung^{a*}, Bharat Bhushan Aggarwal^b, Ilkay Erdogan Orhan^c, Olaf K. Horbańczuk[#], Davide Barreca^e, Maurizio Battino^f, Tarun Belwal^g, Anupam Bishayee^h, Maria Daglia^{am}, Hari Prasad Devkotaⁱ, Javier Echeverría^k, Amr El-Demerdash^{lm}, Aneliya Balachevaⁿ, Maya Georgievaⁿ, Keith Godfrey^o, Vijai Kumar Gupta^p, Jarosław Olav Horbańczuk^q, Lukasz Huminiecki^r, Artur Józwiak^q, Nina Strzalkowska^q, Andrei Mocan^s, Ioana Mozos^t, Seyed Mohammad Nabavi^u, Tamara Pajpanovaⁿ, Valeria Pittalà^v, Joanna Feder-Kubis^w, Silvestre Sampino^q, Ana Sanches Silva^{xy}, Helen Sheridan^z, Antoni Sureda^{aa}, Devesh Tewari^{ab}, Dongdong Wang^q, Volkmar Weissig^{ac}, Yang Yang^q, Gökhan Zengin^{ad}, Karuna Shanker^{ae}, Mohammad Amin Moosavi^{af}, Muhammad Ajmal Shah^{ag}, Ekaterina Kozuharova^{ah}, Fuad Al-Rimawi^{ai}, Alessandra Durazzo^{aj}, Massimo Lucarini^{aj}, Eliana B. Souto^{ak,al}, Antonello Santini^{am}, Clemens Malainer^{an}, Dimitar Djilianov^{ao}, Lyubka P. Tancheva^{ap}, Hua-Bin Li^{ar}, Ren-You Gan^{as}, Nikolay T. Tzvetkovnd, Atanas G. Atanasov^{q,at*}

^a Oral and Maxillofacial Radiology, Applied Oral Sciences, Faculty of Dentistry, The University of Hong Kong, Hong Kong S.A.R., China (ndyeung@hku.hk)

^b Inflammation Research Center, San Diego, CA, United States

^c Faculty of Pharmacy, Gazi University, Ankara, Turkey

[#] Faculty of Human Nutrition and Consumer Sciences, Warsaw University of Life Sciences, 02-776 Warsaw, Poland

^d Pharmaceutical Institute, University of Bonn, Bonn, Germany

* Corresponding authors: ndyeung@hku.hk and a.atanasov.mailbox@gmail.com

- ^o Biochemistry and Applied Biochemistry, Università degli studi di Messina, Messina, Italy
- ^f Nutrition and Food Science Group, Department of Analytical and Food Chemistry, CITACA, CACTI, University of Vigo, Vigo Campus, Vigo, Spain
- ^g Centre of Biodiversity Conservation and Management, G. B. Pant National Institute of Himalayan Environment and Sustainable Development, Kosi-Katarmal, Almora, Uttarakhand, India
- ^h Lake Erie College of Osteopathic Medicine, 5000 Lakewood Ranch Boulevard, Bradenton, FL 34211, USA
- ⁱ Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia, Pavia, Italy
- ^j Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
- ^k Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago, Chile
- ^l Centre National de La recherche Scientifique, Muséum National d'Histoire Naturelle, Molécules de Communication et Adaptation des Micro-organismes, UMR 7245 CNRS/MNHN, Sorbonne Universités, France
- ^m Organic Chemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Mansoura 35516, Egypt
- ⁿ Department of Biochemical Pharmacology and Drug Design, Institute of Molecular Biology "Roumen Tsanev", Bulgarian Academy of Sciences, Sofia, Bulgaria
- ^o MRC Lifecourse Epidemiology Unit and NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust
- ^p ERA Chair of Green Chemistry, Department of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia
- ^q The Institute of Genetics and Animal Breeding, Polish Academy of Sciences, Jastrzębiec, 05-552 Magdalenka, Poland
- ^r SciLifeLab, IGP, Uppsala University, Uppsala, Sweden
- ^s Department of Pharmaceutical Botany, "Iuliu Hațieganu" University of Medicine and Pharmacy, 23 Ghe. Marinescu Street, 400337 Cluj-Napoca, Romania
- ^t Discipline of Pathophysiology, Victor Babes University of Medicine and Pharmacy of Timisoara, Timișoara, Romania
- ^u Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, P.O. Box 19395-5487, Tehran 14359-16471, Iran
- ^v Department of Drug Science, University of Catania, Catania, Italy
- ^w Wrocław University of Science and Technology, Faculty of Chemistry, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Poland
- ^x National Institute for Agricultural and Veterinary Research (INIAV), Vairão, Vila do Conde, Portugal
- ^y Center for Study in Animal Science (CECA), ICETA, University of Porto, Oporto, Portugal
- ^z School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Ireland
- ^{aa} Research Group on Community Nutrition and Oxidative Stress (NUCOX) and CIBEROBN (Physiopathology of Obesity and Nutrition CB12/03/30038), University of Balearic Islands, Palma de Mallorca E-07122, Balearic Islands, Spain
- ^{ab} Department of Pharmaceutical Sciences, Faculty of Technology, Kumaun University, Nainital, Uttarakhand, India

- ^{ac} Department of Pharmaceutical Sciences, Midwestern University, Glendale, AZ, USA
- ^{ad} Department of Biology, Selcuk University, Konya, Turkey
- ^{ae} Analytical Chemistry Department, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, 226015, India
- ^{af} Department of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, P.O Box:14965/161, Tehran, Iran
- ^{ag} Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad 38000, Pakistan
- ^{ah} Department of Pharmacognosy, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
- ^{ai} Department of Chemistry and Chemical Technology, Faculty of Science and Technology, Al-Quds University, Jerusalem, Palestine
- ^{aj} CREA-Research Centre for Food and Nutrition, ViaArdeatina 546, 00178 Rome, Italy
- ^{ak} Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Polo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
- ^{al} CEB-Centre of Biological Engineering, University of Minho, Campus de Gualtar,4710-057 Braga, Portugal
- ^{am} Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy
- ^{an} Independent Researcher, Vienna, Austria.
- ^{ao} Abiotic Stress Group, Agrobiointitute, Agricultural Academy, 1164 Sofia, Bulgaria
- ^{ap} Department of Behavioral Neurobiology, Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia, Bulgaria
- ^{ar} Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangdong Engineering Technology Research Center of Nutrition Translation, Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, China
- ^{as} Department of Food Science & Technology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai 200240, China
- ^{at} Department of Pharmacognosy, University of Vienna, Vienna, Austria

(Accepted March 29, 2019)

Resveratrol is a stilbene-type bioactive molecule with a broad spectrum of reported biological effects. In this sense, the current work provides a comprehensive literature analysis on resveratrol, representing a highly-researched commercially available dietary ingredient. Bibliometric data were identified by means of the search string TOPIC=(“resveratrol*”) and analyzed with the VOSviewer software, which yielded 17,561 publications extracted from the Web of Science Core Collection electronic database. The ratio of original articles to reviews was 9.5:1. More than half of the overall manuscripts have been published since 2013. Major contributing countries were USA, China, Italy, South Korea, and Spain. Most of the publications appeared in journals specialized in biochemistry and molecular biology, pharmacology and pharmacy, food science technology, cell biology, or oncology. The phytochemicals or phytochemical classes that were frequently mentioned in the keywords of analyzed publications included, in descending order: resveratrol, *trans*-resveratrol, polyphenols, flavonoids, quercetin, stilbenes, curcumin, piceatannol, *cis*-resveratrol, and anthocyanins.

KEYWORDS: bibliometrics / biological activities / cancer / citation analysis / pharmacology / resveratrol / Web of Science / VOSviewer

Resveratrol (systematically named 3,5,4'-trihydroxy-*trans*-stilbene) is a phytoalexin stilbenoid [Akinwumi *et al.* 2018] mainly found in the skin of grapes and many other dietary plants such as raspberries, mulberries, pistachios and peanuts. It is hypothesized that resveratrol is produced in response to stress conditions, including injury and microbial attack [Jang *et al.* 1997, Frémont 2000, Rocha-González *et al.* 2008, Tabeshpour *et al.* 2018]. Numerous investigations have reported its potential usefulness in the prevention and treatment of cardiovascular diseases, hepatic disorders, diabetes, cancer, obesity, pain, inflammation, tissue injury, neurodegeneration, and even aging [Rocha-González *et al.* 2008, Bishayee *et al.* 2010b, Darvesh *et al.* 2010, Chachay *et al.* 2011, Sinha *et al.* 2016, Ko *et al.* 2017, Öztürk *et al.* 2017, Koushki *et al.* 2018, Pannu and Bhatnagar 2019, Springer and Moco 2019]. The antioxidant properties of resveratrol promote the reduction of arterial stiffness, which is a factor contributing to the development of cardiovascular diseases [Mozos and Luca 2017, Mozos *et al.* 2017, Wang *et al.* 2018, Uhrin *et al.* 2018]. Resveratrol has been considered responsible for the “French paradox”, explaining the comparatively low incidence of coronary heart disease despite consumption of high fat diet in France, where higher amounts of red wine (rich of resveratrol) are consumed [Kopp 1998]. In relation to the latter, it has been argued that resveratrol's bio-effects are observed at concentrations higher than the concentrations typically found in red wine, but important consideration also is the synergistic action of resveratrol with other compounds found in red wine [Chan *et al.* 2000, Kurin *et al.* 2012]. Additionally, the antidiabetic, antiviral and anti-microbial activity of resveratrol are also well documented [Koushki *et al.* 2018]. Because of its multiple potential health benefits, resveratrol is a frequently mentioned phytochemical in natural product research [Yeung *et al.* 2018a]. This compound is also present in varied and ever-growing nutraceuticals and food supplements [Santini *et al.* 2013, Andrew and Izzo 2017, Santini *et al.* 2017, Durazzo *et al.* 2018, Santini *et al.* 2018]. Resveratrol exists in two isomeric forms, i.e., the *cis*- and *trans*-isomer, both of which can be bound to glucose [Mattivi *et al.* 1995]. *Trans*-resveratrol is supposed to be present in grape skins, whereas *cis*-resveratrol is found in red wine, in variable concentration [López-Hernández *et al.* 2007]. Though only *trans*-resveratrol is commercially available as a purified nutraceutical, the pharmacokinetic and pharmacodynamic properties of both isomers appear to be similar [Orallo 2006]. Resveratrol has been found to activate human SIRT1 (sirtuin 1) protein, which mediates anti-proliferative and anti-inflammatory activities via gene expression alterations and metabolic pathway modulations and thus exhibits many potential beneficial health effects [Borra *et al.* 2005, Mohar and Malik 2012, Ajami *et al.* 2017, Deus *et al.* 2017, Cătană *et al.* 2018, Humieniecki and Horbańczuk 2018, Mohan *et al.* 2018]. On the other hand, the bioavailability of resveratrol is poor because of its rapid metabolism leading to high concentrations of its metabolites in plasma [Chachay *et al.* 2011, Pannu and Bhatnagar 2019].

With the large number of available publications, our literature analysis could identify major research topics, and also summarize and categorize the citation data of contributors from different levels (institutions, countries, and journals) and topics. Similar analyses have already been performed for the fields of ethnopharmacology [Yeung *et al.* 2018c], food sciences [Yeung 2018], nutraceuticals [Yeung *et al.* 2018d], neuropharmacology [Yeung *et al.* 2018e, Yeung *et al.* 2019a], and oncology [Yeung *et al.* 2018b].

The current analysis was aimed at evaluating research publications on resveratrol to identify the major contributing institutions, countries/regions, and journals. Another purpose of this work was to identify the major research topics of resveratrol literature, and reveal the chemicals/chemical classes that were frequently co-investigated and discussed along with resveratrol.

Material and methods

In December 2018, we accessed the Web of Science (WoS) Core Collection electronic database (Clarivate Analytics, Philadelphia, PA, USA) to identify publications containing the word “resveratrol” or its derivatives in the title, abstract, or keywords using for this purpose the search string: TOPIC=(“resveratrol*”). Since the chemical formula of resveratrol is 3,5,4'-trihydroxy-*trans*-stilbene, we conducted an exploratory search to assess if we missed some publications that only listed the chemical formula but not the word “resveratrol” itself or its derivatives. For this purpose, we used the search string: TOPIC=(“3,5,4'-trihydroxy-*trans*-stilbene”) NOT TOPIC=(“resveratrol*”), which yielded no results, thus confirming that our initial approach was correct. No extra restriction was considered on the search strategy, such as publication language or publication year.

Data extraction

The publications identified from the search were evaluated for (1) publication year; (2) author’s affiliations; (3) country/region of the affiliations; (4) journal title; (5) WoS category; (6) publication type; (7) language; and (8) total citation count. The full records and cited references of these identified publications were extracted and analyzed by the VOSviewer software for bibliometrics.

The VOSviewer software was also applied to analyze the semantic contents of titles, abstracts, and keywords of publications in order to relate them to the citation data count and synthesize a bubble map to visualize the results [van Eck and Waltman 2009]. For the current work, we used default settings of the software for the analyses and syntheses of the bubble map. The bubble size in the bubble map indicates the frequency of occurrence (multiple appearances in a single publication count as one) of the words. Words are clustered if they co-occurred in the analyzed publications more frequently. Only words that appeared in at least 1% ($n = 176$) of the publications were analyzed and visualized.

Results and discussion

The literature search resulted in 17,561 publications. The earliest resveratrol-related publication indexed in WoS dated from 1976, and investigated the production of resveratrol by plants of the family Vitaceae in response to infection or injury [Langcake and Pryce 1976]. More than half of the overall publications has been published since the year 2013 of which a large number originates from China (publications since 2013 = 2,407; 72.9% of China's total publications), which reflects the increasing research interest in natural products in general [Atanasov *et al.* 2015]. The ratio of original articles ($n = 13,821$) to reviews ($n = 1,459$) was 9.5:1. Most of the publications were written in English ($n = 17,348$; 98.8%). Contributions came from 7,720 institutions (authors' affiliations) located in 135 countries/territories and were published in 2,751 different journals. The top five WoS categories of the publications were biochemistry and molecular biology ($n = 2,850$; 16.2%), pharmacology and pharmacy ($n = 2,723$; 15.5%), food science technology ($n = 1,980$; 11.3%), cell biology ($n = 1,443$; 8.2%), and oncology ($n = 1,361$; 7.8%). Top five contributors with regard to journal, institution and country/territory are listed in Table 1. In particular, we noticed that the number of publications that appeared in the journal *Molecules* largely increased after 2013 due to the introduction of its "Metabolites" section, together with its open access policy and apparent preference for Chinese researchers. Though the French National Institute of Health and Medical Research is the largest contributing institution, France was not within the top 5 countries. The large number of contributions from the USA, China and Italy was similar to their respective shares in the fields of antioxidant,

Table 1. Top five contributor journals, institutions, and countries/territories of the analyzed 17,561 publications

Contributor	Publication count (% of total)	Citation per manuscript
Journal		
Journal of Agricultural and Food Chemistry	432 (2.5%)	51.7
PLOS One	313 (1.8%)	26.7
FASEB Journal	292 (1.7%)	17.4
Food Chemistry	239 (1.4%)	30.5
Molecules	170 (1.0%)	12.3
Institution		
French National Institute of Health and Medical Research	267 (1.5%)	57.3
National Institutes of Health (USA)	244 (1.4%)	83.5
University of California	243 (1.4%)	54.2
National Research Council (Italy)	206 (1.2%)	46.5
University of Texas	198 (1.1%)	76.6
Country / Territory		
USA	4,148 (23.6%)	44.8
China	3,300 (18.8%)	15.5
Italy	1,277 (7.3%)	33.2
South Korea	1,042 (5.9%)	23.5
Spain	1,027 (5.8%)	38.9

ethnopharmacology, and natural products research [Yeung *et al.* 2018a, Yeung *et al.* 2018b, Yeung *et al.* 2018c, Yeung *et al.* 2019b].

There were 422 terms that appeared in at least 1% ($n = 176$) of the analyzed titles and abstracts (Fig. 1). Some major themes were related to: treatment ($n = 4,555$, citations per publication; CPP = 26.4), mechanism ($n = 3,479$; CPP = 35.0), apoptosis ($n = 2,159$; CPP = 33.4), cancer ($n = 1,840$; CPP = 39.5), diet ($n = 1,021$; CPP = 45.5), oxidative stress ($n = 1,656$; CPP = 28.9), inflammation ($n = 1,179$; CPP = 33.0), and antioxidant ($n = 1,064$; CPP = 35.7).




Fig. 1. Bubble map visualizing words from titles and abstracts of the 17,561 resveratrol publications. Only words that appeared in at least 1% ($n = 176$) of the publications' titles and abstracts were analyzed and visualized by VOSviewer software. There were 422 terms that appeared in at least 1% of the analyzed publications. The bubble color indicates the averaged citations received by publications with the specific words. The bubble size indicates the appearance frequency of the words (multiple appearances in a single manuscript count as one). Two words are closer to each other if they co-occurred more frequently in the analyzed publications.

There were 133 keywords that were used in at least 1% of the publications (Fig. 2). It could be observed that *in vitro* ($n = 1,474$; CPP = 26.1) was listed in more publications as a keyword than *in vivo* ($n = 640$; CPP = 30.3), with mice ($n = 822$; CPP = 23.3) and rats ($n = 637$; CPP = 24.7) being the most common animal models. Some of the most commonly mentioned diseases or conditions were Alzheimer's disease ($n = 404$; CPP = 32.5), breast cancer ($n = 303$; CPP = 29.9), obesity ($n = 289$; CPP = 24.4), atherosclerosis ($n = 257$; CPP = 45.1), and coronary heart disease ($n = 180$; CPP = 56.5). The most frequent sources of studied dietary resveratrol were red wine ($n = 1,142$; CPP = 47.0), grapes ($n = 398$; CPP = 41.0), and green tea ($n = 180$; CPP = 45.5). Concerning the natural sources from which resveratrol is extracted, only the plant Latin name *Vitis*




Fig. 3. Chemical structures of key single chemicals or representatives of chemical classes that were often discussed in the analyzed resveratrol-related publications.

effects, it has been found that resveratrol exerts analgesic and anti-inflammatory activities in mice and rats [Wang *et al.* 2017]. Resveratrol also improved the health and survival of mice on a high-calorie diet [Baur *et al.* 2006], which led to the inference that health-beneficial effects of resveratrol are similar to those achieved by calorie restriction (CR) and mediated through induction of autophagy, an intracellular catabolic process that maintains cell survival under stressful conditions [Dutta *et al.* 2014, Moosavi *et al.* 2018]. A combination of CR and resveratrol improved cardiovascular health in 26-month-old rats [Dutta *et al.* 2014]. In addition, resveratrol was also found to exert a protective effect against the toxicity of dioxins to which larvae of *Drosophila melanogaster* were exposed [Çolak and Uysal 2017]. On the other hand, however, resveratrol has also been associated with harms to animal health. For example, resveratrol has been linked to promoting atherosclerosis in rabbits fed with high cholesterol diet [Wilson *et al.* 1996]. Concerning its anti-cancerous effect, animal studies have yielded mixed results, depending on the route of administration, dose, tumor model, and species [Carter *et al.* 2014].

The dose of resveratrol needed for physiological adaptations in humans is different from that required for animals [Lagouge *et al.* 2006]. This may be attributable to

the difference in the metabolism rate of resveratrol between humans and animals [Hsieh and Wu 2010, Kuršvietienė *et al.* 2016]. Recent reviews have encouraged the conduction of better designed studies conducting more human clinical trials, as current evidence is scant and does not always confirm the beneficial effects reported from in vitro and animal studies [Bishayee 2009, Smoliga *et al.* 2011, Tomé-Carneiro *et al.* 2013, Singh *et al.* 2015, Berman *et al.* 2017, Ramírez-Garza *et al.* 2018]. For example, clinical studies conducted on patients diagnosed with cancer yield ambiguous results, depending on the type of cancer [Berman *et al.* 2017]. Results from a phase 2 trial of resveratrol tested on patients with mild to moderate Alzheimer's disease revealed that resveratrol was safe and well-tolerated and could penetrate the blood-brain barrier (BBB) to have effects on the central nervous system (CNS) [Turner *et al.* 2015, Terawi *et al.* 2018]. One particular problem encountered is the dose translation from animal models to humans, for which no gold standard is yet available. The body surface area normalization method rather than a simple conversion by body weight is a preferable standard [Reagan-Shaw *et al.* 2008]. A high absorption accompanied by a low bioavailability of resveratrol through oral ingestion in humans is yet another downside [Walle *et al.* 2004]. All of these factors imply that more efforts are necessary to evaluate the promising beneficial effects, especially anti-inflammatory, chemopreventive and anticancer therapeutic activities of resveratrol, observed in multiple in vitro and in vivo models [Jang *et al.* 1997, Manna *et al.* 2000, Ashikawa *et al.* 2002, Banerjee *et al.* 2002, Estrov *et al.* 2003, Aggarwal *et al.* 2004, Bhardwaj *et al.* 2007, Harikumar and Aggarwal 2008, Bishayee and Dhir 2009, Shakibaei *et al.* 2009, Bishayee *et al.* 2010a, Bishayee *et al.* 2010c, Harikumar *et al.* 2010, Gupta *et al.* 2011, Mbimba *et al.* 2012, Buhrmann *et al.* 2017, Humieniecki *et al.* 2017, Buhrmann *et al.* 2018, Islam *et al.* 2018, Mozos *et al.* 2018, Wang *et al.* 2018].

No analysis was conducted on the authorship of resveratrol publications, as many of the most abundant authors had Chinese names, which shared the same initials, thus complicating an accurate analysis. For instance, according to the data analyzed, the most prolific author for the analyzed resveratrol publications was “Zhang Y.,” which name upon a closer examination revealed to represent multiple authors: Zhang Yongqing, Zhang Yan, Zhang Yong, and a few others. Analyzing authorship by full names was also not feasible since some records only listed the authors' first names as initials.

Conclusions

The findings based on the analysis of the publications on resveratrol revealed that some of the most significant contributors came from the USA, China, Italy, South Korea, and Spain. Most of the publications focused on biochemistry and molecular biology, pharmacology and pharmacy, food science technology, cell biology, or oncology. More than 50% of them have been published since 2013, which could be attributed in part to the increased research activity in China. Frequently investigated diseases or conditions included Alzheimer's disease, breast cancer, obesity, atherosclerosis, and coronary heart

disease. This work could be used for a brief overview of resveratrol-related research landscape, in order to identify open windows for future research on resveratrol or its derivatives.

Acknowledgments: *Atanas G. Atanasov and Dongdong Wang acknowledge the support by the Polish KNOW (Leading National Research Centre) Scientific Consortium “Healthy Animal - Safe Food,” decision of Ministry of Science and Higher Education No. 05-1/KNOW2/2015 and the European Union under the European Regional Development Fund (Homing/2017-4/41). Antoni Sureda was supported by the Institute of Health Carlos III (Project CIBEROBN CB12/03/30038).*

Conflict of interest: The authors declare no conflict of interest.

Author contributions: AWKY and AGA conceived the work, performed data collection, analyses and drafted the manuscript. All authors critically reviewed and revised the manuscript, and approved its submission for publication in the journal *Animal Science Papers and Reports*.

REFERENCES

1. AGGARWAL B.B., BHARDWAJ A., AGGARWAL R.S., SEERAM N.P., SHISHODIA S., TAKADA, Y., 2004 - Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. *Anticancer Research* 24, 2783-2840.
2. AJAMI M., PAZOKI-TOROUDI H., AMANI H., NABAVI S.F., BRAIDY N., VACCA R. A., ATANASOV A.G., MOCAN A., NABAVI S.M., 2017 - Therapeutic role of sirtuins in neurodegenerative disease and their modulation by polyphenols. *Neuroscience and Biobehavioral Reviews* 73, 39-47.
3. AKINWUMI B., BORDUN K.A., ANDERSON H., 2018 - Biological activities of stilbenoids. *International journal of molecular sciences* 19, 792.
4. ALBAYRAK S., AKSOY A., SAGDIC O., HAMZAOGLU E., 2010 - Compositions, antioxidant and antimicrobial activities of *Helichrysum* (Asteraceae) species collected from Turkey. *Food Chemistry* 119, 114-122.
5. ANDREW R., IZZO A.A., 2017 - Principles of pharmacological research of nutraceuticals. *British Journal of Pharmacology* 174, 1177-1194.
6. ASHIKAWA K., MAJUMDAR S., BANERJEE S., BHARTIA C., SHISHODIA S., AGGARWAL B. B., 2002 - Piceatannol inhibits TNF-induced NF- κ B activation and NF- κ B-mediated gene expression through suppression of I κ B α kinase and p65 phosphorylation. *The Journal of Immunology* 169, 6490-6497.
7. ATANASOV A.G., WALTENBERGER B., PFERSCHY-WENZIG E.-M., LINDER T., WAWROSCHE C., UHRIN P., TEMML V., WANG L., SCHWAIGER S., HEISS E.H., 2015 - Discovery and resupply of pharmacologically active plant-derived natural products: a review. *Biotechnology advances* 33, 1582-1614.
8. BANERJEE S., BUESO-RAMOS C., AGGARWAL B.B., 2002 - Suppression of 7, 12-dimethylbenz (a) anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor- κ B, cyclooxygenase 2, and matrix metalloproteinase 9. *Cancer Research* 62, 4945-4954.
9. BAUR J.A., PEARSON K.J., PRICE N.L., JAMIESON H.A., LERIN C., KALRA A., PRABHU V.V., ALLARD J.S., LOPEZ-LLUCH G., LEWIS K., 2006 - Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 444, 337.

10. BERMAN A.Y., MOTECHIN R.A., WIESENFELD M.Y., HOLZ M.K., 2017 - The therapeutic potential of resveratrol: a review of clinical trials. *NPJ precision oncology* 1, 35.
11. BHARDWAJ A., SETHI G., VADHAN-RAJ S., BUESO-RAMOS C., TAKADA Y., GAUR U., NAIR A.S., SHISHODIA S., AGGARWAL B.B., 2007 - Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor- κ B-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. *Blood* 109, 2293-2302.
12. BISHAYEE A., 2009 - Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. *Cancer prevention research* 2, 409-418.
13. BISHAYEE A., BARNES K.F., BHATIA D., DARVESH A.S., CARROLL R.T., 2010a - Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. *Cancer prevention research* 3, 753-763.
14. BISHAYEE A., DARVESH A.S., POLITIS T., MCGORY R., 2010b - Resveratrol and liver disease: from bench to bedside and community. *Liver International* 30, 1103-1114.
15. BISHAYEE A., DHIR N., 2009 - Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. *Chemico-Biological Interactions* 179, 131-144.
16. BISHAYEE A., WAGHRAY A., BARNES K.F., MBIMBA T., BHATIA D., CHATTERJEE M., DARVESH A.S., 2010c - Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. *Pharmaceutical Research* 27, 1080-1091.
17. BORRA M.T., SMITH B.C., DENU J.M., 2005 - Mechanism of human SIRT1 activation by resveratrol. *Journal of Biological Chemistry* 280, 17187-17195.
18. BUHRMANN C., POPPER B., AGGARWAL B.B., SHAKIBAEI M., 2017 - Resveratrol downregulates inflammatory pathway activated by lymphotoxin α (TNF- β) in articular chondrocytes: Comparison with TNF- α . *PLoS One* 12, e0186993.
19. BUHRMANN C., YAZDI M., POPPER B., SHAYAN P., GOEL A., AGGARWAL B., SHAKIBAEI M., 2018 - Resveratrol chemosensitizes TNF- β -induced survival of 5-FU-treated colorectal cancer cells. *Nutrients* 10, 888.
20. CARTER L.G., D'ORAZIO J.A., PEARSON K. J., 2014 - Resveratrol and cancer: a focus on in vivo evidence. *Endocrine-Related Cancer* 21, R209-R225.
21. CĂTANĂ C.-S., MEHTEROV N., ATANASOV A.G., BERINDAN-NEAGOE I., 2018 - Natural products with anti-aging potential: affected targets and molecular mechanisms. *Biotechnology advances* 36, 1649-1656.
22. CHACHAY V. S., KIRKPATRICK C.M., HICKMAN I.J., FERGUSON M., PRINS J. B., MARTIN J.H., 2011 - Resveratrol—pills to replace a healthy diet? *British Journal of Clinical Pharmacology* 72, 27-38.
23. CHAN M.M.-Y., MATTIACCI J.A., HWANG H. S., SHAH A., FONG D., 2000 - Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric oxide synthase pathway. *Biochemical Pharmacology* 60, 1539-1548.
24. ÇOLAK D.A., UYSAL, H., 2017 - Protective effects of coenzyme Q10 and resveratrol on oxidative stress induced by various dioxins on transheterozigot larvae of *Drosophila melanogaster*. *Toxicology Research* 6, 521-525.
25. DARVESH A.S., CARROLL R.T., BISHAYEE A., GELDENHUYS W. J., VAN DER SCHYF C.J., 2010 - Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents. *Expert Review of Neurotherapeutics* 10, 729-745.
26. DEUS C.M., SERAFIM T.L., MAGALHÃES-NOVAIS S., VILAÇA A., MOREIRA A.C., SARDÃO V.A., CARDOSO S.M., OLIVEIRA P.J., 2017 - Sirtuin 1-dependent resveratrol cytotoxicity and pro-differentiation activity on breast cancer cells. *Archives of Toxicology* 91, 1261-1278.

27. DURAZZO A., D'ADDEZIO L., CAMILLI E., PICCINELLI R., TURRINI A., MARLETTA L., MARCONI S., LUCARINI M., LISCIANI S., GABRIELLI P., 2018 - From plant compounds to botanicals and back: A current snapshot. *Molecules* 23, 1844.
28. DUTTA D., XU J., DIRAIN M.L., LEEUWENBURGH C., 2014 - Calorie restriction combined with resveratrol induces autophagy and protects 26-month-old rat hearts from doxorubicin-induced toxicity. *Free Radical Biology and Medicine* 74, 252-262.
29. ESTROV Z., SHISHODIA S., FADERL S., HARRIS D., VAN Q., KANTARJIAN H.M., TALPAZ M., AGGARWAL B.B., 2003 - Resveratrol blocks interleukin-1 β -induced activation of the nuclear transcription factor NF- κ B, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. *Blood* 102, 987-995.
30. FRÉMONT L., 2000 - Biological effects of resveratrol. *Life Sciences* 66, 663-673.
31. GUPTA S.C., KANNAPPAN R., REUTER S., KIM J.H., AGGARWAL B.B., 2011 - Chemosensitization of tumors by resveratrol. *Annals of the New York Academy of Sciences* 1215, 150-160.
32. HARIKUMAR K.B., AGGARWAL B.B., 2008 - Resveratrol: a multitargeted agent for age-associated chronic diseases. *Cell cycle* 7, 1020-1035.
33. HARIKUMAR K.B., KUNNUMAKKARA A.B., SETHI G., DIAGARADJANE P., ANAND P., PANDEY M.K., GELOVANI J., KRISHNAN S., GUHA S., AGGARWAL B.B., 2010 - Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. *International Journal of Cancer* 127, 257-268.
34. HSIEH T.C., WU J. M., 2010 - Resveratrol: Biological and pharmaceutical properties as anticancer molecule. *Biofactors* 36, 360-369.
35. HUMINIECKI L., HORBAŃCZUK J., 2018 - The functional genomic studies of resveratrol in respect to its anti-cancer effects. *Biotechnology Advances*, doi: 10.1016/j.biotechadv.2018.02.011.
36. HUMINIECKI L., HORBAŃCZUK J., ATANASOV A.G., 2017 - The functional genomic studies of curcumin. *Seminars in Cancer Biology*, doi.org/10.1016/j.semcancer.2017.04.002.
37. ISLAM M.T., ALI E.S., UDDIN S.J., SHAW S., ISLAM M.A., AHMED M.I., CHANDRA SHILL M., KARMAKAR U.K., YARLA N.S., KHAN I.N., BILLAH M.M., PIECZYŃSKA M.D., ZENGIN G., MALAINER C., NICOLETT, F., GULE, D., BERINDAN-NEAGOE I., APOSTOLOV A., BANACH M., YEUNG A.W.K., EL-DEMERDASH A., XIAO J., DEY P., YELE S., JÓŻWIK A., STRZAŁKOWSK, N., MARCHEWKA J., RENGASAMY K.R.R., HORBAŃCZUK J., KAMAL M.A., MUBARAK M.S., MISHRA S.K., SHILPI J.A., ATANASOV A.G., 2018 - Phytol: A review of biomedical activities. *Food and Chemical Toxicology* 121, 82-94.
38. JANG M., CAI L., UDEANI G.O., SLOWING K.V., THOMAS C.F., BEECHER C.W., FONG H.H., FARNSWORTH N.R., KINGHORN A.D., MEHTA R.G., 1997 - Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. *Science* 275, 218-220.
39. JEONG H.S., HONG S.J., CHO J.Y., LEE T.-B., KWON J.-W., JOO H.J., PARK J.H., YU C.W., LIM D.-S., 2016 - Effects of *Rubus occidentalis* extract on blood pressure in patients with prehypertension: Randomized, double-blinded, placebo-controlled clinical trial. *Nutrition* 32, 461-467.
40. KO J.-H., SETHI G., UM J.-Y., SHANMUGAM M.K., ARFUSO F., KUMAR A.P., BISHAYEE A., AHN K.S., 2017 - The role of resveratrol in cancer therapy. *International journal of molecular sciences* 18, 2589.
41. KOPP P., 1998 - Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? *European Journal of Endocrinology* 138, 619-620.
42. KOUSHKI M., AMIRI-DASHATAN N., AHMADI N., ABBASZADEH H.A., REZAEI-TAVIRANI M., 2018 - Resveratrol: A miraculous natural compound for diseases treatment. *Food Science & Nutrition* 6, 2473-2490.
43. KURIN E., ATANASOV A.G., DONATH O., HEISS E.H., DIRSCH V.M., NAGY M., 2012 -

- Synergy study of the inhibitory potential of red wine polyphenols on vascular smooth muscle cell proliferation. *Planta Medica* 78, 772-778.
44. KURŠVIETIENĖ L., STANEVIČIENĖ I., MONGIRDIENĖ A., BERNATONIENĖ J., 2016 - Multiplicity of effects and health benefits of resveratrol. *Medicina* 52, 148-155.
 45. LAGOUGE M., ARGMANN C., GERHART-HINES Z., MEZIANE H., LERIN C., DAUSSIN F., MESSADEQ N., MILNE J., LAMBERT P., ELLIOTT P., 2006 - Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 α . *Cell* 127, 1109-1122.
 46. LANGCAKE P., PRYCE R., 1976 - The production of resveratrol by *Vitis vinifera* and other members of the Vitaceae as a response to infection or injury. *Physiological Plant Pathology* 9, 77-86.
 47. LÓPEZ-HERNÁNDEZ J., PASEIRO-LOSADA P., SANCHES-SILVA A.T., LAGE-YUSTY M.A., 2007 - Study of the changes of trans-resveratrol caused by ultraviolet light and determination of trans-and cis-resveratrol in Spanish white wines. *European Food Research and Technology* 225, 789-796.
 48. MANNA S.K., MUKHOPADHYAY A., AGGARWAL B.B., 2000 - Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF- κ B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. *The Journal of Immunology* 164, 6509-6519.
 49. MATTIVI F., RENIERO F., KORHAMMER S., 1995 - Isolation, characterization, and evolution in red wine vinification of resveratrol monomers. *Journal of Agricultural and Food Chemistry* 43, 1820-1823.
 50. MBIMBA T., AWALE P., BHATIA D.J., GELDENHUYS W.S., DARVESH A.T., CARROLL R., BISHAYEE A., 2012 - Alteration of hepatic proinflammatory cytokines is involved in the resveratrol-mediated chemoprevention of chemically-induced hepatocarcinogenesis. *Current Pharmaceutical Biotechnology* 13, 229-234.
 51. MOHAN S., GOBINATH T., SALOMY A., NISHA M., KANDASAMY M., MOHAMED ESSA M., JAYACHANDRAN K.S., ANUSUYADEVI M., 2018 - Biophysical interaction of resveratrol with sirtuin pathway: significance in Alzheimer's disease. *Frontiers Bioscience* 23, 1380-1390.
 52. MOHAR, D. S., MALIK, S., 2012 - The sirtuin system: the holy grail of resveratrol? *Journal of Clinical & Experimental Cardiology* 3, 216.
 53. MOOSAVI M.A., HAGHI A., RAHMATI M., TANIGUCHI H., MOCAN A., ECHEVERRÍA J., GUPTA V.K., TZVETKOV N.T., ATANASOV A.G., 2018 - Phytochemicals as potent modulators of autophagy for cancer therapy. *Cancer Letters* 424, 46-69.
 54. MOZOS I., LUCA C.T., 2017 - Crosstalk between oxidative and nitrosative stress and arterial stiffness. *Current Vascular Pharmacology* 15, 446-456.
 55. MOZOS I., MALAINER C., HORBAŃCZUK J., GUG C., STOIAN D., LUCA C.T., ATANASOV A.G., 2017 - Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases. *Frontiers Immunology*.
 56. MOZOS I., STOIAN D., CARABAA., MALAINER C., HORBAŃCZUK J., ATANASOV A., 2018 - Lycopene and vascular health. *Frontiers in Pharmacology*, 9, 521, doi: 10.3389/fphar.2018.00521.
 57. ORALLO F., 2006 - Comparative studies of the antioxidant effects of cis-and trans-resveratrol. *Current Medicinal Chemistry* 13, 87-98.
 58. ÖZTÜRK E., ARSLAN A.K.K., YERER M.B., BISHAYEE A., 2017 - Resveratrol and diabetes: A critical review of clinical studies. *Biomedicine and Pharmacotherapy* 95, 230-234.
 59. PANNU N., BHATNAGAR A., 2019 - Resveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases. *Biomedicine and Pharmacotherapy* 109, 2237-2251.
 60. RAMÍREZ-GARZA S., LAVERIANO-SANTOS E., MARHUENDA-MUÑOZ M., STORNILOLO C., TRESSERRA-RIMBAU A., VALLVERDÚ-QUERALT A., LAMUELA-RAVENTÓS R., 2018 - Health effects of resveratrol: Results from human intervention trials. *Nutrients* 10, 1892.

61. REAGAN-SHAW S., NIHAL M., AHMAD N., 2008 - Dose translation from animal to human studies revisited. *The FASEB journal* 22, 659-661.
62. RIMANDO, A. M., KALT, W., MAGEE, J. B., DEWEY, J., BALLINGTON, J. R., 2004 - Resveratrol, pterostilbene, and piceatannol in vaccinium berries. *Journal of Agricultural and Food Chemistry* 52, 4713-4719.
63. ROCHA-GONZÁLEZ H.I., AMBRIZ-TUTUTI M., GRANADOS-SOTO V., 2008 - Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. *CNS Neuroscience & Therapeutics* 14, 234-247.
64. SANTINI A., CAMMARATA S.M., CAPONE G., IANARO A., TENORE G.C., PANI L., NOVELLINO E., 2018 - Nutraceuticals: opening the debate for a regulatory framework. *British Journal of Clinical Pharmacology* 84, 659-672.
65. SANTINI A., NOVELLINO E., ARMINI V., RITIENI A., 2013 - State of the art of Ready-to-Use Therapeutic Food: a tool for nutraceuticals addition to foodstuff. *Food Chemistry* 140, 843-849.
66. SANTINI A., TENORE G.C., NOVELLINO E., 2017 - Nutraceuticals: A paradigm of proactive medicine. *European Journal of Pharmaceutical Sciences* 96, 53-61.
67. SCHRÖDER J., SCHRÖDER G., 1990 - Stilbene and chalcone synthases: related enzymes with key functions in plant-specific pathways. *Zeitschrift für Naturforschung C* 45, 1-8.
68. SHAKIBAEI M., HARIKUMAR K.B., AGGARWAL B.B., 2009 - Resveratrol addiction: to die or not to die. *Molecular nutrition & food research* 53, 115-128.
69. SINGH C.K., NDIAYE M.A., AHMAD N., 2015 - Resveratrol and cancer: Challenges for clinical translation. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 1852, 1178-1185.
70. SINHA D., SARKAR N., BISWAS J., BISHAYEE A., 2016 - Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms. *Seminars in Cancer Biology* 40, 209-232.
71. SMOLIGA J.M., BAUR J. A., HAUSENBLAS H. A., 2011 - Resveratrol and health—a comprehensive review of human clinical trials. *Molecular nutrition & food research* 55, 1129-1141.
72. SPRINGER, M., MOCO, S., 2019 - Resveratrol and Its Human Metabolites—Effects on Metabolic Health and Obesity. *Nutrients* 11, 143.
73. TABESHPOUR J., MEHRI S., SHAEBANI BEHBAHANI F., HOSSEINZADEH H., 2018 - Protective effects of *Vitis vinifera* (grapes) and one of its biologically active constituents, resveratrol, against natural and chemical toxicities: A comprehensive review. *Phytotherapy Research* 32, 2164-2190.
74. TEWARI D., STANKIEWICZ A., MOCAN A., SAH A., HUMINIECKI L., HORBAŃCZUK J.O., ATANASOV A.G., 2018- Ethnopharmacological approaches for management of dementia and the therapeutic significance of natural products and herbal drugs. *Frontiers in Aging Neuroscience*, doi:10.3389/fnagi.2018.00003.
75. TOMÉ-CARNEIRO J., LARROSA M., GONZÁLEZ-SARRÍAS A.A., TOMAS-BARBERAN F., TERESA GARCIA-CONESA M., CARLOS ESPIN J., 2013 - Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. *Current Pharmaceutical Design* 19, 6064-6093.
76. TURNER R.S., THOMAS R.G., CRAFT S., VAN DYCK C.H., MINTZER J., REYNOLDS B.A., BREWER J.B., RISSMAN R.A., RAMAN R., AISEN P.S., 2015 - A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. *Neurology* 85, 1383-1391.
77. UHRIN P., WANG D., MOCAN A., WALTENBERGER B., TEWARI D., HUMINIECKI Ł., STARZYŃSKI R.F., TZVETKOV N.T., HORBAŃCZUK J., ATANASOV A.G., 2018 - Vascular smooth muscle cell proliferation as a therapeutic target. Part 2: Natural products inhibiting proliferation. *Biotechnology Advances*. <https://doi.org/10.1016/j.biotechadv.2018.04.002>.
78. VAN ECK N.J., WALTMAN L., 2009 - Software survey: VOSviewer, a computer program for bibliometric mapping. *Scientometrics* 84, 523-538.

79. VARELA M.C., ARSLAN I., REGINATO M.A., CENZANO A. M., LUNA M.V., 2016 - Phenolic compounds as indicators of drought resistance in shrubs from Patagonian shrublands (Argentina). *Plant Physiology and Biochemistry* 104, 81-91.
80. WALLE T., HSIEH F., DELEGGE M.H., OATIS J.E., WALLE U.K., 2004 - High absorption but very low bioavailability of oral resveratrol in humans. *Drug metabolism and disposition* 32, 1377-1382.
81. WANG G., HU Z., SONG X., CUI Q., FU Q., JIA R., ZOU Y., LI L., YIN Z., 2017 - Analgesic and anti-inflammatory activities of resveratrol through classic models in mice and rats. *Evidence-Based Complementary and Alternative Medicine* 2017, 5197567.
82. WANG S.Y., CHEN C.T., WANG C.Y., CHEN P., 2007 - Resveratrol content in strawberry fruit is affected by preharvest conditions. *Journal of Agricultural and Food Chemistry* 55, 8269-8274.
83. WANG D., ÖZEN C., ABU-REIDAH I.M., CHGURUPATI S., PATRA J.K., HORBAŃCZUK J.O., JÓŻWIK A., TZVETKOV N.T., UHRIN P., ATANASOV A.G., 2018 - Vasculoprotective effects of pomegranate (*Punica granatum* L.). *Frontiers in Pharmacology* 9:544 doi: 10.3389/fphar.2018.00544.
84. WANG D., UHRIN P., MOCAN A., WALTENBERGER B., BREUSS J.M., TEWARI D., MIHALY-BISON J., HUMINIECKI Ł., STARZYŃSKI R.F., TZVETKOV N.T., HORBAŃCZUK J., ATANASOV A.G., 2018 - Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways. *Biotechnology Advances* <https://doi.org/10.1016/j.biotechadv.2018.04.006>.
85. WILSON T., KNIGHT T.J., BEITZ D.C., LEWIS D.S., ENGEN R.L., 1996 - Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. *Life Sciences* 59, PL15-PL21.
86. YEUNG A.W.K., 2018 - Bibliometric study on functional magnetic resonance imaging literature (1995-2017) concerning chemosensory perception. *Chemosensory Perception* 11, 42-50.
87. YEUNG A.W.K., ABDEL-DAIM M.M., ABUSHOUK A.I., KADONOSONO K., 2019a - A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach. *Naunyn-Schmiedeberg's Archives of Pharmacology* 392, 393-403.
88. YEUNG A.W.K., AGGARWAL B., BARREC, D., BATTINO M., BELWAL T., HORBAŃCZUK O., BERINDAN-NEAGOE I., BISHAYEE A., DAGLIA M., DEVKOTA H., ECHEVERRÍA J., EL-DEMERDASH A., ORHAN I., GODFREY K., GUPTA V., HORBAŃCZUK J., MODLIŃSKI J., HUBER L., HUMINIECKI Ł., JÓŻWIK A., MARCHEWKA J., MILLER M., MOCAN A., MOZOS I., NABAVI S., NABAVI S., PIECZYŃSKA M., PITTALÀ V., RENGASAMY K., SILVA A., SHERIDAN H., STANKIEWICZ A., STRZAŁKOWSKA N., SUREDA A., TEWARI D., WEISSIG, V., ZENGİN G., ATANASOV A., 2018a - Dietary natural products and their potential to influence health and disease including animal model studies. *Animal Science Papers and Reports* 36, 345-358.
89. YEUNG A.W.K., EL-DEMERDASH A., BERINDAN-NEAGOE I., ATANASOV A.G., HO Y.-S., 2018b - Molecular Responses of Cancers by Natural Products: Modifications of Autophagy Revealed by Literature Analysis. *Critical Reviews in Oncogenesis* 23, 347-370.
90. YEUNG A.W.K., HEINRICH M., ATANASOV A.G., 2018c - Ethnopharmacology - A Bibliometric Analysis of a Field of Research Meandering Between Medicine and Food Science? *Frontiers in Pharmacology* 9, 215.
91. YEUNG A.W.K., MOCAN A., ATANASOV A.G., 2018d - Let food be thy medicine and medicine be thy food: A bibliometric analysis of the most cited papers focusing on nutraceuticals and functional foods. *Food Chemistry* 269, 455-465.
83. YEUNG A.W.K., TZVETKOV N.T., ATANASOV A.G., 2018e - When neuroscience meets pharmacology: a neuropharmacology literature analysis. *Frontiers in Neuroscience* 12, 852.
84. YEUNG A.W.K., TZVETKOV N.T., EL-TAWIL O.S., BUNGĂU S.G., ABDEL-DAIM M.M., ATANASOV A.G., 2019b - Antioxidants: Scientific Literature Landscape Analysis. *Oxidative Medicine and Cellular Longevity* 2019, 8278454.